Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1 : The EXPEDITION-2 Study

Autor: Rockstroh, Jürgen K., Lacombe, Karine, Viani, Rolando M., Orkin, Chloe, Wyles, David, Luetkemeyer, Anne F., Soto-Malave, Ruth, Flisiak, Robert, Bhagani, Sanjay, Sherman, Kenneth E., Shimonova, Tatiana, Ruane, Peter, Sasadeusz, Joseph, Slim, Jihad, Zhang, Zhenzhen, Samanta, Suvajit, Ng, Teresa I., Gulati, Abhishek, Kosloski, Matthew P., Shulman, Nancy S., Trinh, Roger, Sulkowski, Mark

Publikováno v: Clinical Infectious Diseases, 2018 Oct 01. 67(7), 1010-1017.

Externí odkaz: https://www.jstor.org/stable/26526673

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.

Autor: Lassman, Andrew B, Pugh, Stephanie L, Wang, Tony J C, Aldape, Kenneth, Gan, Hui K, Preusser, Matthias, Vogelbaum, Michael A, Sulman, Erik P, Won, Minhee, Zhang, Peixin, Moazami, Golnaz, Macsai, Marian S, Gilbert, Mark R, Bain, Earle E, Blot, Vincent, Ansell, Peter J, Samanta, Suvajit, Kundu, Madan G, Armstrong, Terri S, Wefel, Jeffrey S

Publikováno v: Neuro-Oncology; Feb2023, Vol. 25 Issue 2, p339-350, 12p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Double-blind Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo in Patients Nave to Biologic Disease modifying Antirheumatic Drugs with Psoriatic Arthritis

Autor: Mease, Philip, Van Der Heijde, Desiree, Ritchlin, Christopher, Cuchacovich, Raquel, Shuler, Catherine, Lin, Chen-Yen, Vangerow, Harold, Samanta, Suvajit, Lee, Chin, Gladman, Dafna, Kurzawa, Monika

Publikováno v: 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20160831-20160903; Frankfurt am Main; DOCRA.44 /20160829/

Background: Ixekizumab (IXE) is an anti-IL-17A monoclonal antibody under investigation for PsA treatment. Methods: 417 biologic disease modifying antirheumatic drug (bDMARD)-naive patients with active psoriatic arthritis (PsA) were randomized to plac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee88a6ef1962609ccc4c4aafb36fa06

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.